Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
BPC-157 — short for "Body Protection Compound 157" — is a synthetic 15-amino-acid sequence that researchers isolated from a larger gastric juice protein known as BPC. The original work was published in 1991 by Predrag Sikiric and colleagues at the University of Zagreb, and the lab in Croatia has produced the bulk of the published research in the three decades since.
The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is stable in human gastric juice for over 24 hours — a property that makes it unusual among peptides and one of the reasons it has been studied through both oral and injectable routes.
History and research stage
The peptide was developed as a tool for studying ulcer healing. Early animal work in the 1990s found that BPC-157 accelerated healing of gastric and duodenal lesions in rats. From there, the Sikiric group expanded the investigation into tendon, ligament, muscle, nerve, and vascular healing — almost always in rodents, almost always at intraperitoneal or oral doses far higher than the human-equivalent quantities sold today.
There is no published Phase II or Phase III human trial. A small number of Phase I-style human pharmacokinetic and tolerability reports exist but most remain unpublished. The compound has never been submitted as a drug application to any major regulator.
Regulatory status
BPC-157 has no approved medical use anywhere in the world. In November 2023, the FDA placed it in Category 2 of the 503A bulk substances list, the category for substances that "raise significant safety risks." That designation effectively bars compounding pharmacies in the United States from preparing BPC-157 for patients. The World Anti-Doping Agency added BPC-157 to its banned list in 2022 under the S0 (non-approved substances) category.
In the European Union it is unscheduled but unauthorized for therapeutic use. Sales in most jurisdictions are routed through "research chemical" suppliers with explicit not-for-human-use labeling.
How researchers describe its action
The published mechanism papers describe BPC-157 as a modulator of nitric oxide signaling, an upregulator of VEGFR2 (a key receptor in blood vessel formation), and an enhancer of growth hormone receptor expression in tendon cells. The hypothesis common to most reviews is that BPC-157 acts on multiple healing pathways at once rather than a single receptor — which is part of why no clean target-based human trial has emerged.
It is important to note: every one of these mechanism claims comes from preclinical work. None has been demonstrated in a controlled human study at the doses typically used.
Half-life and dosing intervals
The half-life of BPC-157 in circulation is short — published estimates put it at roughly 15 to 30 minutes after subcutaneous injection. Despite that, animal studies report sustained effects after once-daily dosing, which the authors attribute to downstream pathway activation that outlasts the parent peptide.
In published rodent studies, common research doses range from 10 to 250 micrograms per kilogram per day — most often given as a single daily injection. Subcutaneous and intraperitoneal routes have been used most frequently.
There is no established human dose. The doses commonly described in observational human use online (typically 250–500 mcg once or twice daily) are extrapolations from animal data, not from controlled trials. Because no Phase II safety data exists, neither long-term safety nor an upper limit has been characterized.
Reconstitution example
BPC-157 is sold as a lyophilized (freeze-dried) powder in 5 mg or 10 mg vials. A common reconstitution for a 5 mg vial is to add 2 mL of bacteriostatic water, yielding a concentration of 2.5 mg/mL — meaning 0.1 mL on a 1 mL insulin syringe (10 units on a U-100 syringe) contains 250 mcg.
For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, the same 10-unit mark contains 500 mcg. Vial's calculator handles this conversion automatically when you enter the vial mass and water volume.
What to know
- Limited human data. Almost all efficacy evidence is preclinical. Long-term human safety has not been characterized in any controlled trial.
- Not approved. Compounding pharmacies in the United States cannot legally prepare BPC-157 for patients, and it is banned in competitive sport.
- Storage. Lyophilized BPC-157 is stable at room temperature for short periods but is best stored refrigerated and protected from light. Once reconstituted, refrigerate and use within 4 weeks per the stability data published by the Sikiric group.
- Common reported side effects in user reports include injection-site irritation and transient headaches. Serious adverse events have not been documented in the published literature, but the absence of large human trials means the safety profile is incomplete.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Seiwerth S et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Frontiers in Pharmacology.
- 3.FDA 503A Bulk Drug Substances list — Category 2 (November 2023).
- 4.Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology.